Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer test that can help doctors identify those early-stage patients at high risk for progression to late-stage disease. Lung cancer is currently the leading cause of cancer deaths worldwide, claiming close to 1.5 million lives every year.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.